Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?

Andrew Z Wang

doi:10.1016/j.ebiom.2014.11.013

Abstract

Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?

Highlights

Despite the success of targeted therapies, many genomic alterations are considered “undruggable”
Nanoparticles can protect the small interfering RNA (siRNA) from degradation and can facilitate endosomal escape once the siRNA has been endocytosed by the target cells (Kanasty et al, 2013)
No siRNA-based therapies have been approved for clinical use

Summary

Introduction

Despite the success of targeted therapies, many genomic alterations are considered “undruggable”. The effects of siRNA are temporary (days to weeks) and not permanent; such temporary effects may not last long enough to alter the disease course.

Results

Conclusion